Shares of Cybin Inc. (NASDAQ:HELP – Get Free Report) saw an uptick in trading volume on Monday. 7,874,852 shares traded hands during trading, an increase of 503% from the average daily volume of 1,306,700 shares. The stock last traded at $7.3410 and had previously closed at $8.87.
Analyst Ratings Changes
Several research analysts have commented on the stock. Barclays initiated coverage on shares of Cybin in a report on Friday, September 18th. They issued an “overweight” rating and a $35.00 price target for the company. TD Cowen upped their price target on shares of Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Wells Fargo & Company upped their price target on shares of Cybin from $16.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Finally, Wall Street Zen downgraded Cybin from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Six analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $47.33.
View Our Latest Report on Cybin
Cybin Price Performance
The firm has a market capitalization of $628.82 million, a PE ratio of -2.61 and a beta of 0.64. The business’s 50 day moving average is $11.24 and its two-hundred day moving average is $7.81.
Cybin (NASDAQ:HELP – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.74). Analysts expect that Cybin Inc. will post -2.95 EPS for the current fiscal year.
Insider Activity at Cybin
In other news, CEO Michael Halstead purchased 100,000 shares of the stock in a transaction on Monday, September 21st. The shares were acquired at an average price of $13.47 per share, for a total transaction of $1,347,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,568 shares of the company’s stock, valued at approximately $2,270,610.96. This trade represents a 145.84% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Greg Cavers purchased 3,000 shares of the stock in a transaction on Tuesday, September 29th. The shares were purchased at an average price of $12.91 per share, for a total transaction of $38,730.00. Following the transaction, the chief financial officer directly owned 3,000 shares of the company’s stock, valued at approximately $38,730. This represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 688,000 shares of company stock valued at $8,422,830 over the last ninety days. 15.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Cybin
A number of large investors have recently modified their holdings of the company. AXQ Capital LP bought a new stake in Cybin in the 2nd quarter worth approximately $75,000. Farther Finance Advisors LLC grew its position in Cybin by 927.4% during the third quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock valued at $280,000 after acquiring an additional 20,597 shares during the last quarter. State Street Corp bought a new position in Cybin during the third quarter valued at approximately $363,000. Pale Fire Capital SE purchased a new position in shares of Cybin during the second quarter worth approximately $1,015,000. Finally, WealthPlan Investment Management LLC purchased a new position in shares of Cybin during the third quarter worth approximately $1,272,000. 17.94% of the stock is owned by hedge funds and other institutional investors.
About Cybin
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
Featured Articles
- Five stocks we like better than Cybin
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
